Cambridge Investment Research Advisors
DFTX icon

Cambridge Investment Research Advisors’s Definium Therapeutics DFTX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$248K Buy
+5,267
New +$130K ﹤0.01% 3613
2021
Q4 		– Sell
-962
Closed -$34K – 3236
2021
Q3 		$34K Buy
+962
New +$41.6K ﹤0.01% 3041

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Cambridge Investment Research Advisors's DFTX Position: Q2 2026 in Review

Cambridge Investment Research Advisors opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 5,267 shares worth $248K. The stake represents ﹤0.01% of the portfolio and ranks #3613 among its holdings. This is a return to the name: Cambridge Investment Research Advisors previously reported a position in DFTX as recently as Q3 2021.

Cambridge Investment Research Advisors first reported a position in DFTX in Q3 2021 and has held it in 2 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Cambridge Investment Research Advisors held 5,267 shares of Definium Therapeutics worth $248K as of Q2 2026.
  • Definium Therapeutics was a new Cambridge Investment Research Advisors position in Q2 2026.
  • Definium Therapeutics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3613 holding.
  • Cambridge Investment Research Advisors first reported a position in Definium Therapeutics in Q3 2021 and has held it in 2 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.